Kuniko Mitamura

Dr. Kuniko Mitamura

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
KSKanta Sato
Kanta Sato
NNNoriaki Nagai
Noriaki Nagai
TYTetsushi Yamamoto
Tetsushi Yamamoto
KMKuniko Mitamura
Kuniko Mitamura
ATAtsushi Taga
Atsushi Taga
The incidence of diabetes mellitus (DM) is increasing rapidly and is associated with changes in dietary habits. Although restrictions in the use of sweeteners may prevent the development of DM, this might reduce the quality of life of patients with DM. Therefore, there has been a great deal of research into alternative sweeteners. In the search for such sweeteners, we analyzed the carbohydrate content of maple syrup and identified a novel oligosaccharide composed of fructose and glucose, linked at the C-4 of glucose and the C-6 of fructose. This oligosaccharide inhibited the release of fructose from sucrose by invertase (IC50: 1.17 mmol/L) and the decomposition of maltose by α-(1-4) glucosidase (IC50: 1.72 mmol/L). In addition, when orally administered together with sucrose to rats with DM, the subsequent plasma glucose concentrations were significantly lower than if the rats had been administered sucrose alone, without having any effect on the insulin concentration. These findings suggest that this novel oligosaccharide might represent a useful alternative sweetener for inclusion in the diet of patients with DM and may also have therapeutic benefits.

1 August 2007 in Journal of Chromatography B
Verified
Journal Article
Closed access
KMKuniko Mitamura
Kuniko Mitamura
MSMitsuru Sogabe
Mitsuru Sogabe
HSHironori Sakanashi
Hironori Sakanashi
SWSaai Watanabe
Saai Watanabe
TSToshihiro Sakai
Toshihiro Sakai
SIShigeo Ikegawa
Shigeo Ikegawa

24 March 2023 in Journal of Lipid Research
Verified
Journal Article
Open access
KMKei Minowa
Kei Minowa
DRDaniel Rodriguez-Agudo
Daniel Rodriguez-Agudo
MSMitsuyoshi Suzuki
Mitsuyoshi Suzuki
YMYamato Muto
Yamato Muto
SHSaeko Hirai
Saeko Hirai
GKGenta Kakiyama
Genta Kakiyama
CYP7B1 catalyzes mitochondria-derived cholesterol metabolites such as (25R)26-hydroxycholesterol (26HC) and 3β-hydroxy-5-cholesten-(25R)26-oic acid (3βHCA) and facilitates their conversion to bile acids. Disruption of 26HC/3βHCA metabolism in the absence of CYP7B1 leads to neonatal liver failure. Disrupted 26HC/3βHCA metabolism with reduced hepatic CYP7B1 expression is also found in nonalcoholic steatohepatitis (NASH). The current study aimed to understand the regulatory mechanism of mitochondrial cholesterol metabolites and their contribution to onset of NASH. We used Cyp7b1−/− mice fed a normal diet (ND), Western diet (WD), or high-cholesterol diet (HCD). Serum and liver cholesterol metabolites as well as hepatic gene expressions were comprehensively analyzed. Interestingly, 26HC/3βHCA levels were maintained at basal levels in ND-fed Cyp7b1−/− mice livers by the reduced cholesterol transport to mitochondria, and the upregulated glucuronidation and sulfation. However, WD-fed Cyp7b1−/− mice developed insulin resistance (IR) with subsequent 26HC/3βHCA accumulation due to overwhelmed glucuronidation/sulfation with facilitated mitochondrial cholesterol transport. Meanwhile, Cyp7b1−/− mice fed an HCD did not develop IR or subsequent evidence of liver toxicity. HCD-fed mice livers revealed marked cholesterol accumulation but no 26HC/3βHCA accumulation. The results suggest 26HC/3βHCA-induced cytotoxicity occurs when increased cholesterol transport into mitochondria is coupled to decreased 26HC/3βHCA metabolism driven with IR. Supportive evidence for cholesterol metabolite-driven hepatotoxicity is provided in a diet-induced nonalcoholic fatty liver mouse model and by human specimen analyses. This study uncovers an insulin-mediated regulatory pathway that drives the formation and accumulation of toxic cholesterol metabolites within the hepatocyte mitochondria, mechanistically connecting IR to cholesterol metabolite-induced hepatocyte toxicity which drives nonalcoholic fatty liver disease.

1 July 2014 in Steroids
Verified
Journal Article
Closed access
KMKuniko Mitamura
Kuniko Mitamura
RORika Satoh (Née Okihara)
Rika Satoh (Née Okihara)
MKMami Kamibayashi
Mami Kamibayashi
KSKanta Sato
Kanta Sato
TITakashi Iida
Takashi Iida
SIShigeo Ikegawa
Shigeo Ikegawa

20 December 2021 in Foods
Verified
Journal Article
Open access
PDF file
KSKanta Sato
Kanta Sato
TYTetsushi Yamamoto
Tetsushi Yamamoto
KMKuniko Mitamura
Kuniko Mitamura
ATAtsushi Taga
Atsushi Taga
Fructosyl oligosaccharides, including fructo-oligosaccharide (FOS), are gaining popularity as functional oligosaccharides and have been found in various natural products. Our previous study suggested that maple syrup contains an unidentified fructosyl oligosaccharide. Because these saccharides cannot be detected with high sensitivity using derivatization methods, they must be detected directly. As a result, an analytical method based on charged aerosol detection (CAD) that can detect saccharides directly was optimized in order to avoid relying on these structures and physical properties to clarify the profile of fructosyl oligosaccharides in maple syrup. This analytical method is simple and can analyze up to hepta-saccharides in 30 min. This analytical method was also reliable and reproducible with high validation values. It was used to determine the content of saccharides in maple syrup, which revealed that it contained not only fructose, glucose, and sucrose but also FOS such as 1-kestose and nystose. Furthermore, we identified neokestose as a maple syrup content. It has only been found in a few natural foods as a fructosyl oligosaccharide. These findings help to shed light on the saccharides profile of maple syrup.